188 related articles for article (PubMed ID: 17652823)
1. Novel antioxidants in anthracycline cardiotoxicity.
Hideg K; Kálai T
Cardiovasc Toxicol; 2007; 7(2):160-4. PubMed ID: 17652823
[TBL] [Abstract][Full Text] [Related]
2. Antioxidant defense against anthracycline cardiotoxicity by metallothionein.
Kang YJ
Cardiovasc Toxicol; 2007; 7(2):95-100. PubMed ID: 17652812
[TBL] [Abstract][Full Text] [Related]
3. The nitroxides pirolin and pirolid protect the plasma membranes of rat cardiomyocytes against damage induced by anthracyclines.
Koceva-Chyła A; Sokal A; Kania K; Gwoździński K; Jóźwiak Z
Cell Mol Biol Lett; 2003; 8(1):171-7. PubMed ID: 12655371
[TBL] [Abstract][Full Text] [Related]
4. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
5. Cytoprotective agents for anthracyclines.
Dorr RT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
[TBL] [Abstract][Full Text] [Related]
6. Are cardioprotective effects of NO-releasing drug molsidomine translatable to chronic anthracycline cardiotoxicity settings?
Lenčová-Popelová O; Jansová H; Jirkovský E; Bureš J; Jirkovská-Vávrová A; Mazurová Y; Reimerová P; Vostatková L; Adamcová M; Hroch M; Pokorná Z; Kovaříková P; Šimůnek T; Štěrba M
Toxicology; 2016 Nov; 372():52-63. PubMed ID: 27816693
[TBL] [Abstract][Full Text] [Related]
7. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
[TBL] [Abstract][Full Text] [Related]
8. Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials.
Bast A; Haenen GR; Bruynzeel AM; Van der Vijgh WJ
Cardiovasc Toxicol; 2007; 7(2):154-9. PubMed ID: 17652822
[TBL] [Abstract][Full Text] [Related]
9. Early and delayed cardioprotective intervention with dexrazoxane each show different potential for prevention of chronic anthracycline cardiotoxicity in rabbits.
Jirkovský E; Lenčová-Popelová O; Hroch M; Adamcová M; Mazurová Y; Vávrová J; Mičuda S; Šimůnek T; Geršl V; Štěrba M
Toxicology; 2013 Sep; 311(3):191-204. PubMed ID: 23831762
[TBL] [Abstract][Full Text] [Related]
10. Schisandrin B prevents doxorubicin-induced cardiotoxicity via enhancing glutathione redox cycling.
Li L; Pan Q; Han W; Liu Z; Li L; Hu X
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6753-60. PubMed ID: 18006777
[TBL] [Abstract][Full Text] [Related]
11. Role of exogenous melatonin in reducing the cardiotoxic effect of daunorubicin and doxorubicin in the rat.
Dziegiel P; Jethon Z; Suder E; Sopel M; Rabczyński J; Surowiak P; Zabel M
Exp Toxicol Pathol; 2002 Feb; 53(6):433-9. PubMed ID: 11926284
[TBL] [Abstract][Full Text] [Related]
12. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
Menna P; Salvatorelli E; Minotti G
Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
[TBL] [Abstract][Full Text] [Related]
13. Other uses of dexrazoxane: Savene, the first proven antidote against anthracycline extravasation injuries.
Langer SW; Jensen PB; Sehested M
Cardiovasc Toxicol; 2007; 7(2):151-3. PubMed ID: 17652821
[TBL] [Abstract][Full Text] [Related]
14. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
Conklin KA
Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
[TBL] [Abstract][Full Text] [Related]
15. Cardiotoxicity and comparative pharmacokinetics of six anthracyclines in the rabbit.
Jaenke RS; Deprez-DeCampeneere D; Trouet A
Cancer Res; 1980 Oct; 40(10):3530-6. PubMed ID: 6934026
[TBL] [Abstract][Full Text] [Related]
16. Genotyping the risk of anthracycline-induced cardiotoxicity.
Deng S; Wojnowski L
Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
[TBL] [Abstract][Full Text] [Related]
17. Screening of antioxidants from medicinal plants for cardioprotective effect against doxorubicin toxicity.
Wattanapitayakul SK; Chularojmontri L; Herunsalee A; Charuchongkolwongse S; Niumsakul S; Bauer JA
Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):80-7. PubMed ID: 15667600
[TBL] [Abstract][Full Text] [Related]
18. The role of biotransformation in anthracycline-induced cardiotoxicity in mice.
de Jong J; Schoofs PR; Snabilié AM; Bast A; van der Vijgh WJ
J Pharmacol Exp Ther; 1993 Sep; 266(3):1312-20. PubMed ID: 8371139
[TBL] [Abstract][Full Text] [Related]
19. Angelica sinensis: a novel adjunct to prevent doxorubicin-induced chronic cardiotoxicity.
Xin YF; Zhou GL; Shen M; Chen YX; Liu SP; Chen GC; Chen H; You ZQ; Xuan YX
Basic Clin Pharmacol Toxicol; 2007 Dec; 101(6):421-6. PubMed ID: 17971065
[TBL] [Abstract][Full Text] [Related]
20. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
